Cladribine is used for treating multiple sclerosis (MS) with oral cladribine. It was first introduced by Janssen Pharmaceuticals Inc in its drug Leustatin on Feb 26, 1993. Another drug containing Cladribine is Mavenclad. 6 different companies have introduced drugs containing Cladribine.

Cladribine Patents

Given below is the list of patents protecting Cladribine, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Mavenclad	US10849919	Cladribine regimen for treating progressive forms of multiple sclerosis	Nov 23, 2038	Emd Serono Inc
Mavenclad	US7713947	Cladribine regimen for treating multiple sclerosis	Oct 16, 2026	Emd Serono Inc
Mavenclad	US8377903	Cladribine regimen for treating multiple sclerosis	May 31, 2026	Emd Serono Inc
Mavenclad	US7888328	Oral formulations of cladribine	Apr 11, 2024 (Expired)	Emd Serono Inc
Mavenclad	US8785415	Oral formulations of cladribine	Apr 11, 2024 (Expired)	Emd Serono Inc

Add above patents to watchlist

Cladribine's Family Patents

Full family tree

Cladribine Generic API Manufacturers

Several generic applications have been filed for Cladribine. The first generic version for Cladribine was by Hikma Pharmaceuticals Usa Inc and was approved on Feb 28, 2000. And the latest generic version is by Hisun Pharmaceutical (Hangzhou) Co Ltd and was approved on Nov 25, 2019.

Given below is the list of companies who have filed for Cladribine generic, along with the locations of their manufacturing plants worldwide.